Serotonergic agents
AssigneeWyeth
InventorsWayne E. Childers, Michael G. Kelly, Sharon J. Rosenzweig-Lipson
Life of this patent
Estimating the term…
Abstract
Novel piperazine derivatives are provided having the formula 1 wherein R1 is cyano, nitro, trifluoromethyl or halogen, or pharmaceutically acceptable acid addition salts thereof, which are useful as 5-HT1A receptor antagonists.
Claims12
A method for treating memory deficits or cognitive disorders in a patient in need thereof, comprising providing to the patient a therapeutically effective amount of a compound of formula (III):
- 8
- wherein R1 is cyano, nitro, trifluoromethyl or halogen, or pharmaceutically acceptable acid addition salts thereof.
A method for treating alcohol, nicotine and drug withdrawal in a patient in need thereof, comprising providing to the patient a therapeutically effective amount of the compound of formula (III):
- 9
- wherein R1 is cyano, nitro, trifluoromethyl or halogen, or pharmaceutically acceptable acid addition salts thereof.
A method for treating Parkinson's disease and motor disorders in a patient in need thereof, comprising administering to the patient an effective amount of a compound of Formula III:
- 10
- wherein R1 is cyano, nitro, trifluoromethyl or halogen, or pharmaceutically acceptable acid addition salts thereof.
A method for treating migraine in a patient in need thereof, comprising administering to the patient an effective amount of a compound of formula (III):
- 11
- wherein R1 is cyano, nitro, trifluoromethyl or halogen, or pharmaceutically acceptable acid addition salts thereof.
A method for treating eating disorders in a patient in need thereof, comprising administering to the patient an effective amount of a compound of formula (III):
- 12
- wherein R1 is cyano, nitro, trifluoromethyl or halogen, or pharmaceutically acceptable acid addition salts thereof.
A method for treating sexual dysfunction in a patient in need thereof, comprising administering to the patient an effective amount of a compound of formula (III):
- 13
- wherein R1 is cyano, nitro, trifluoromethyl or halogen, or pharmaceutically acceptable acid addition salts thereof.
A method for treating urinary incontinence in a patient in need thereof, comprising administering to the patient an effective amount of a compound of formula (III):
- 14
- wherein R1 is cyano, nitro, trifluoromethyl or halogen, or pharmaceutically acceptable acid addition salts thereof.
A method for treating stroke in a patient in need thereof, comprising administering to the patient an effective amount of a compound of formula (III):
- 15
- wherein R1 is cyano, nitro, trifluoromethyl or halogen, or pharmaceutically acceptable acid addition salts thereof.
A method for treating endocrine disorders in a patient in need thereof, comprising administering to the patient an effective amount of a compound of formula (III):
- 16
- wherein R1 is cyano, nitro, trifluoromethyl or halogen, or pharmaceutically acceptable acid addition salts thereof.
A method for treating sleep disorders in a patient in need thereof, comprising administering to the patient an effective amount of a compound of formula (III):
- 17
- wherein R1 is cyano, nitro, trifluoromethyl or halogen, or pharmaceutically acceptable acid addition salts thereof.
A method for treating attention deficit disorders in a patient in need thereof, comprising administering to the patient an effective amount of a compound of formula (III):
- 18
- wherein R1 is cyano, nitro, trifluoromethyl or halogen, or pharmaceutically acceptable acid addition salts thereof.
A method for treating Tourette's syndrome, autism, social phobias, hyperactivity disorders or thermoregulatory disorders in a patient in need thereof, comprising administering to the patient an effective amount of a compound of formula (III):
- 19
- wherein R1 is cyano, nitro, trifluoromethyl or halogen, or pharmaceutically acceptable acid addition salts thereof.
Dependencies are inferred from the claim text.